Guo Jian-Gui, Guo Cheng-Cheng, He Zhen-Qiang, Cai Xiu-Yu, Mou Yong-Gao
Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, Guandong 528000, P.R. China.
State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, Guandong 510060, P.R. China.
Oncol Lett. 2018 Aug;16(2):2237-2242. doi: 10.3892/ol.2018.8880. Epub 2018 Jun 4.
To date the management of glioma remains a great challenge in cancer therapy worldwide. The identification of novel diagnostic and therapeutic methods is required. Although there is data indicating that matrix metalloproteinase (MMP)-26 serves an important role in many human cancer types, its clinical significance in glioma remains uncertain. The present study aimed to evaluate MMP-26 expression in human astrocytic glioma specimens, and investigate its role and significance in the progression of astrocytic glioma. Immunohistochemistry was performed to assess MMP-26 expression in astrocytic glioma tissues. The levels of MMP-26 expression and its relevance to the clinicopathological features and prognostic factors in patients with astrocytic glioma patients were then investigated. The results demonstrated that MMP-26 expression was significantly assocaited with the World Health Organization grade (P<0.05). Additionally, it was identified that MMP-26 expression was an effective predictor of the overall survival of patients with astrocytic glioma (P<0.05). Analyses of univariate and multivariate Cox regression confirmed that MMP-26 expression was an independent factor for evaluating the prognosis of astrocytic glioma patients (P<0.05). The current results support that MMP-26 may be a novel indicator of diagnosis and an independent factor for evaluating prognosis in patients with glioma.
迄今为止，胶质瘤的治疗仍是全球癌症治疗领域的一大挑战。需要鉴定新的诊断和治疗方法。尽管有数据表明基质金属蛋白酶（MMP）-26在多种人类癌症类型中发挥重要作用，但其在胶质瘤中的临床意义仍不明确。本研究旨在评估MMP-26在人星形胶质细胞瘤标本中的表达，并探讨其在星形胶质细胞瘤进展中的作用和意义。采用免疫组织化学法评估MMP-26在星形胶质细胞瘤组织中的表达。随后研究了MMP-26的表达水平及其与星形胶质细胞瘤患者临床病理特征和预后因素的相关性。结果表明，MMP-26表达与世界卫生组织分级显著相关（P<0.05）。此外，还发现MMP-26表达是星形胶质细胞瘤患者总生存的有效预测指标（P<0.05）。单因素和多因素Cox回归分析证实，MMP-26表达是评估星形胶质细胞瘤患者预后的独立因素（P<0.05）。目前的结果支持MMP-26可能是胶质瘤患者诊断的新指标和评估预后的独立因素。
